Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426283 · ClinicalTrials.gov registry record · Phase 2
A Study of Flovent in Patients With Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Marc Rothenberg, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT00426283: Completed Phase 2 study of Eosinophilic Esophagitis, sponsored by Marc Rothenberg, MD.
NCT00426283 is a Phase 2 study of Eosinophilic Esophagitis that has completed, run by Marc Rothenberg, MD. The registered enrollment target is 42 participants, below the 863-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00426283, a Phase 2 study of Eosinophilic Esophagitis, has completed, sponsored by Marc Rothenberg, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).
Primary Outcome
Remission is considered achieved when the highest eosinophil count per high power field (hpf) in all esophageal biopsies is \</= 1 eosinophil/hpf after 3 months of therapy.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Flovent
Study Locations (4)
Colorado
- The Children's Hospital of Denver - Aurora
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT00426283 record still lists
NCT00426283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 863-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00426283 reports a single indexed study location in Colorado, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00426283 about?
NCT00426283 is a clinical study titled "A Study of Flovent in Patients With Eosinophilic Esophagitis". The purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).
What is the current status of trial NCT00426283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2007-01. Estimated completion is 2012-03.
What conditions does trial NCT00426283 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT00426283?
The interventions under investigation include: Placebo (OTHER), Flovent (DRUG).
Who is sponsoring clinical trial NCT00426283?
This trial is sponsored by Marc Rothenberg, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00426283 being conducted?
This trial has 4 study locations across Colorado, Ohio, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00426283's enrollment target sits among peer trials
42 32nd of 44 higher than 13 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia